D. Grant

发表

Technologies for the Analysis of Single Nucleotide Polymorphisms—An Overview

D. Grant, 2005 .

2,3,7,8-Tetrachlorodibenzo-p-Dioxin (TCDD)-Inducible Poly-ADP-Ribose Polymerase (TIPARP/PARP7) Catalytic Mutant Mice (TiparpH532A) Exhibit Increased Sensitivity to TCDD-Induced Hepatotoxicity and Lethality

D. Grant, J. Matthews, S. Pettersen, 2021, Toxicological sciences : an official journal of the Society of Toxicology.

Hepatocyte-Specific Deletion of TIPARP, a Negative Regulator of the Aryl Hydrocarbon Receptor, Is Sufficient to Increase Sensitivity to Dioxin-Induced Wasting Syndrome

D. Grant, Chakravarthi Kanduri, J. Matthews, 2018, Toxicological sciences : an official journal of the Society of Toxicology.

Loss of the Mono-ADP-ribosyltransferase, Tiparp, Increases Sensitivity to Dioxin-induced Steatohepatitis and Lethality*

D. Grant, J. Matthews, L. Tamblyn, 2015, The Journal of Biological Chemistry.

Three-dimensional culture and cAMP signaling promote the maturation of human pluripotent stem cell-derived hepatocytes

C. Guillemette, D. Grant, R. Tyndale, 2013, Development.

Variation in enzymes of arylamine procarcinogen biotransformation among bladder cancer patients and control subjects.

D. Grant, G. Darlington, H. Sampson, 2001, Pharmacogenetics.

Pharmacogenetics of the arylamine N-acetyltransferases: a symposium in honor of Wendell W. Weber.

D. Grant, F. Kadlubar, C. Mcqueen, 2000, Drug metabolism and disposition: the biological fate of chemicals.

Generation and functional characterization of arylamine N-acetyltransferase Nat1/Nat2 double-knockout mice.

R. Rozmahel, D. Grant, A. Gaedigk, 2003, Molecular pharmacology.

Homology modelling and structural analysis of human arylamine N-acetyltransferase NAT1: evidence for the conservation of a cysteine protease catalytic domain and an active-site loop.

D. Grant, C. Deloménie, F. Rodrigues‐Lima, 2001, The Biochemical journal.

The role of para-aminophenol in acetaminophen-induced methemoglobinemia in dogs and cats.

D. Grant, A. Cribb, S. McConkey, 2009, Journal of veterinary pharmacology and therapeutics.

Chapter 22 – Pharmacogenetics

D. Grant, 2004 .

Caffeine as a possible cause of ventricular arrhythmias during the healing phase of acute myocardial infarction.

D. Grant, L. Harris, F. Leenen, 1987, The American journal of cardiology.

Genetic analysis of microsomal epoxide hydrolase in patients with carbamazepine hypersensitivity.

M. Pirmohamed, D. Grant, B. Burchell, 1995, Biochemical pharmacology.

Pharmacogenetics of the Human Arylamine N-Acetyltransferases

D. Grant, K. Sugamori, G. Goodfellow, 2000, Pharmacology.

Update on consensus arylamine N-acetyltransferase gene nomenclature.

D. Grant, E. Sim, D. Hein, 2000, Pharmacogenetics.

Human acetyltransferase polymorphisms.

D. Grant, A. Gaedigk, N. C. Hughes, 1997, Mutation research.

Comparative metabolism of carbon tetrachloride in rats, mice, and hamsters using gas uptake and PBPK modeling.

D. Grant, K. Weitz, D. M. Grant, 2000, Journal of toxicology and environmental health. Part A.

Variants of N-acetyltransferase NAT1 and a case-control study of colorectal adenomas.

N. Probst-Hensch, D. Grant, R. Haile, 1998, Pharmacogenetics.

Effect of allopurinol on caffeine disposition in man.

D. Grant, B. Tang, W. Kalow, 1986, British journal of clinical pharmacology.

Reduced 4-aminobiphenyl-induced liver tumorigenicity but not DNA damage in arylamine N-acetyltransferase null mice.

W. Pierce, D. Grant, O. Sanchez, 2012, Cancer letters.

Genotyping of the polymorphic N-acetyltransferase (NAT2*) gene locus in two native African populations.

D. Grant, C. Deloménie, R. Krishnamoorthy, 1996, Pharmacogenetics.

Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression.

D. Grant, U. Meyer, M. Heim, 1990, DNA and cell biology.

Identification and characterization of variant alleles of human acetyltransferase NAT1 with defective function using p-aminosalicylate as an in-vivo and in-vitro probe.

D. Grant, D. Bell, M. Jewett, 1998, Pharmacogenetics.

Nomenclature for N-acetyltransferases.

M. Relling, D. Grant, D. Bell, 1995, Pharmacogenetics.

NAD(P)H:quinone oxidoreductase: polymorphisms and allele frequencies in Caucasian, Chinese and Canadian Native Indian and Inuit populations.

D. Grant, R. Tyndale, E. Sellers, 1998, Pharmacogenetics.

Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases.

D. Grant, T. Rustan, M. Doll, 1993, Carcinogenesis.

Salmonella typhimurium strains expressing human arylamine N-acetyltransferases: metabolism and mutagenic activation of aromatic amines.

D. Grant, P. D. Josephy, L. D. Morrison, 1992, Cancer research.

Relative Contributions of CYP1A2 and CYP2E1 to the Bioactivation and Clearance of 4-Aminobiphenyl in Adult Mice

D. Grant, K. Sugamori, D. Bott, 2015, Drug Metabolism and Disposition.

4 – Pharmacogenetics: Pharmacogenomics

D. Grant, D. Hein, 2017 .

Characterization of the microsomal epoxide hydrolase gene in patients with anticonvulsant adverse drug reactions.

D. Grant, A. Gaedigk, S. Spielberg, 1994, Pharmacogenetics.

Paradoxical Attenuation of Autoimmune Hepatitis by Oral Isoniazid in Wild-Type and N-Acetyltransferase–Deficient Mice

Imir G. Metushi, D. Grant, J. Uetrecht, 2014, Drug Metabolism and Disposition.

Pharmacogenetics of Pharmacoecology: Which Route to Personalized Medicine?

D. Grant, M. Piquette-Miller, G. R. Robertson, 2009, Clinical pharmacology and therapeutics.

Acetylation Pharmacogenetics in Human Liver

D. Grant, M. Eichelbaum, U. Meyer, 2022 .

Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity.

D. Grant, S. Spielberg, B. Tang, 1986, Annals of internal medicine.

Primary aromatic amines and cancer: Novel mechanistic insights using 4-aminobiphenyl as a model carcinogen.

D. Grant, K. Sugamori, Shuang Wang, 2019, Pharmacology & therapeutics.

Liver-Selective Expression of Human Arylamine N-Acetyltransferase NAT2 in Transgenic Mice

D. Grant, K. Sugamori, D. Brenneman, 2011, Drug Metabolism and Disposition.

Microsoft Word-83555450-file00

D. Grant, K. Sugamori, D. Brenneman, 2011 .

In Vivo and in Vitro Metabolism of Arylamine Procarcinogens in Acetyltransferase-Deficient Mice

D. Grant, K. Sugamori, D. Brenneman, 2006, Drug Metabolism and Disposition.

Structures of human arylamine N-acetyltransferases.

D. Grant, 2008, Current drug metabolism.

Polymorphic N‐acetylation of a caffeine metabolite

D. Grant, B. Tang, W. Kalow, 1983, Clinical pharmacology and therapeutics.

Effect of Arylamine Acetyltransferase Nat3 Gene Knockout on N-Acetylation in the Mouse

R. Rozmahel, D. Grant, A. Gaedigk, 2007, Drug Metabolism and Disposition.

Cloning, structural organization, and chromosomal mapping of the human phenol sulfotransferase STP2 gene.

D. Grant, A. Gaedigk, B. Beatty, 1997, Genomics.

Molecular genetics of the N-acetyltransferases.

D. Grant, 1993, Pharmacogenetics.

Cell Type–Specific Roles of CD38 in the Interactions of Isoniazid with NAD+ in the Liver

D. Grant, Junjie Zhu, Jie Lu, 2020, Drug Metabolism and Disposition.

Deficiency of N‐acetyltransferase increases the interactions of isoniazid with endobiotics in mouse liver

D. Grant, Jie Lu, Xiaochao Ma, 2017, Biochemical pharmacology.

Tissue-specific expression and alternative splicing of human microsomal epoxide hydrolase.

D. Grant, A. Gaedigk, J. Leeder, 1997, DNA and cell biology.

Pharmacogenetics and the regulation of gene transcription.

D. Grant, 2004, Pharmacogenetics.

Structurally distinct PARP7 inhibitors provide new insights into the function of PARP7 in regulating nucleic acid-sensing and IFN-β signaling.

Michael S. Cohen, D. Grant, J. Matthews, 2022, Cell chemical biology.

Novel sulfotransferases cloned by RT-PCR: real proteins or PCR artifacts?

D. Grant, A. Gaedigk, P. Lekas, 1998, Chemico-biological interactions.

A simple test for acetylator phenotype using caffeine.

D. Grant, B. Tang, W. Kalow, 1984, British journal of clinical pharmacology.

In memoriam: Werner Kalow, MD (1917–2008)

D. Grant, R. Tyndale, 2008 .

Detoxification pathways in the liver

D. Grant, 1991, Journal of Inherited Metabolic Disease.

Genetic polymorphisms of drug-metabolizing enzymes: molecular mechanisms.

D. Grant, R. Skoda, U. Zanger, 1989, Psychopharmacology series.

Role of polymorphic and monomorphic human arylamine N-acetyltransferases in determining sulfamethoxazole metabolism.

D. Grant, M. Miller, S. Spielberg, 1993, Biochemical pharmacology.

The role of xenobiotic metabolizing enzymes in arylamine toxicity and carcinogenesis: functional and localization studies.

D. Grant, R. Mckinnon, A. Gaedigk, 1997, Mutation research.

Covalent binding of sulfamethoxazole reactive metabolites to human and rat liver subcellular fractions assessed by immunochemical detection.

D. Grant, S. Spielberg, S. Grossman, 1996, Chemical Research in Toxicology.

Further investigations of the role of acetylation in sulphonamide hypersensitivity reactions.

D. Grant, S. Spielberg, A. Cribb, 1996, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

Biotransformation of caffeine, paraxanthine, theophylline, and theobromine by polycyclic aromatic hydrocarbon-inducible cytochrome(s) P-450 in human liver microsomes.

D. Grant, W. Kalow, T. Inaba, 1987, Drug metabolism and disposition: the biological fate of chemicals.

Localization of N-acetyltransferases NAT1 and NAT2 in human tissues.

H. Samaratunga, D. Grant, A. Gaedigk, 2000, Toxicological sciences : an official journal of the Society of Toxicology.

Arylamine N‐Acetyltransferases

D. Grant, 2016 .

Site-directed mutagenesis of recombinant human arylamine N-acetyltransferase expressed in Escherichia coli. Evidence for direct involvement of Cys68 in the catalytic mechanism of polymorphic human NAT2.

D. Grant, J. Dupret, Jean-Marie Dupretl, 1992, The Journal of biological chemistry.

Biotransformation of caffeine by microsomes from human liver. Kinetics and inhibition studies.

B K Tang, M E Campbell, D. Grant, 1987, Biochemical pharmacology.

Isolation and identification of 5-acetylamino-6-formylamino-3-methyluracil as a major metabolite of caffeine in man.

D. Grant, B. Tang, W. Kalow, 1983, Drug metabolism and disposition: the biological fate of chemicals.

Variability in caffeine metabolism

B K Tang, D. Grant, B. Tang, 1983, Clinical pharmacology and therapeutics.

Biochemical mechanisms of drug toxicity

P. G. Wells, D. Grant, J. Uetrecht, 2022, Atkinson's Principles of Clinical Pharmacology.

A SNPshot: pharmacogenetics and the future of drug therapy.

M. Boyce-Jacino, D. Grant, D M Grant, 2000, Trends in biotechnology.

Interindividual variability in the glucuronidation of (S) oxazepam contrasted with that of (R) oxazepam.

D. Grant, B. Tang, W. Kalow, 1995, Pharmacogenetics.

Acetylation pharmacogenetics. The slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver.

D. Grant, M. Eichelbaum, U. Meyer, 1990, The Journal of clinical investigation.

Molecular mechanism of slow acetylation of drugs and carcinogens in humans.

D. Grant, U. Meyer, M. Heim, 1991, Proceedings of the National Academy of Sciences of the United States of America.

Nucleotide sequence of an intronless gene for a human arylamine N-acetyltransferase related to polymorphic drug acetylation.

D. Grant, U. Meyer, M. Blum, 1989, Nucleic acids research.

Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations.

P. Beaune, D. Grant, U. Fuhr, 1996, Pharmacogenetics.

Structural Basis of Substrate-binding Specificity of Human Arylamine N-Acetyltransferases*

Ludmila Dombrovsky, Wolfram Tempel, Peter Loppnau, 2007, Journal of Biological Chemistry.

Evidence for two closely related isozymes of arylamine N‐acetyltransferase in human liver

D. Grant, F. Lottspeich, U. Meyer, 1989, FEBS letters.

3-Methylcholanthrene Induces Chylous Ascites in TCDD-Inducible Poly-ADP-Ribose Polymerase (Tiparp) Knockout Mice

D. Grant, T. Watts, J. Matthews, 2019, International journal of molecular sciences.

Influence of arylamine n‐acetyltransferase, sex, and age on 4‐aminobiphenyl‐induced in vivo mutant frequencies and spectra in mouse liver

D. Grant, K. Sugamori, Shuang Wang, 2012, Environmental and molecular mutagenesis.

Caffeine Consumption Contributes to Skin Intrinsic Fluorescence in Type 1 Diabetes

A. Paterson, D. Grant, P. Cleary, 2015, Diabetes technology & therapeutics.

Increased sensitivity to chemically induced colitis in mice harboring a DNA-binding deficient aryl hydrocarbon receptor

D. Grant, C. Baglole, J. Matthews, 2022, Toxicological sciences : an official journal of the Society of Toxicology.

Reduced Colonic Mucosal Injury in 2,3,7,8-Tetrachlorodibenzo-p-Dioxin Poly ADP-Ribose Polymerase (TIPARP/PARP7)-Deficient Mice

D. Grant, J. Matthews, David Hutin, 2022, International journal of molecular sciences.

Monomorphic and polymorphic human arylamine N-acetyltransferases: a comparison of liver isozymes and expressed products of two cloned genes.

D. Grant, U. Meyer, M. Blum, 1991, Molecular pharmacology.

Expression of monomorphic arylamine N-acetyltransferase (NAT1) in human leukocytes.

D. Grant, M. Miller, S. Spielberg, 1991, The Journal of pharmacology and experimental therapeutics.

Study of the role of the highly conserved residues Arg9 and Arg64 in the catalytic function of human N-acetyltransferases NAT1 and NAT2 by site-directed mutagenesis.

D. Grant, C. Deloménie, R. Krishnamoorthy, 1997, The Biochemical journal.

Changes in consensus arylamine N-acetyltransferase gene nomenclature.

D. Grant, R. Minchin, E. Sim, 2008, Pharmacogenetics and genomics.

5-Methyl-Tetrahydrofolate and the S-Adenosylmethionine Cycle in C57BL/6J Mouse Tissues: Gender Differences and Effects of Arylamine N-Acetyltransferase-1 Deletion

D. Grant, R. Minchin, N. Butcher, 2013, PloS one.

Chemical genetics and proteome-wide site mapping reveal cysteine MARylation by PARP-7 on immune-relevant protein targets

Michael S. Cohen, D. Grant, M. L. Nielsen, 2021, eLife.

Characterization of TCDD-inducible poly-ADP-ribose polymerase (TIPARP/ARTD14) catalytic activity

D. Grant, J. Matthews, L. Tamblyn, 2018, The Biochemical journal.

Polymorphisms of N-acetyltransferase genes.

D. Grant, U. Meyer, M. Blum, 1992, Xenobiotica; the fate of foreign compounds in biological systems.

Development of Fluorinated Analogues of Perhexiline with Improved Pharmacokinetic Properties and Retained Efficacy.

D. Grant, M. Frenneaux, M. Zanda, 2017, Journal of medicinal chemistry.

The impact of sex on hepatotoxic, inflammatory and proliferative responses in mouse models of liver carcinogenesis.

D. Grant, K. Sugamori, D. Bott, 2020, Toxicology.

Nucleotide sequence of a full-length cDNA for arylamine N-acetyltransferase from rabbit liver.

D. Grant, U. Meyer, M. Blum, 1989, Nucleic Acids Research.

N-acetylation pharmacogenetics: a gene deletion causes absence of arylamine N-acetyltransferase in liver of slow acetylator rabbits.

D. Grant, U. Meyer, M. Blum, 1989, Proceedings of the National Academy of Sciences of the United States of America.

N-hydroxylation of 4-aminobiphenyl by CYP2E1 produces oxidative stress in a mouse model of chemically induced liver cancer.

D. Grant, J. McPherson, K. Sugamori, 2015, Toxicological sciences : an official journal of the Society of Toxicology.

Influence of sex and developmental stage on acute hepatotoxic and inflammatory responses to liver procarcinogens in the mouse.

D. Grant, A. E. Riedmaier, K. Sugamori, 2016, Toxicology.

A readout of metabolic efficiency in arylamine N‐acetyltransferase‐deficient mice reveals minor energy metabolism changes

P. Boutros, D. Grant, S. Luquet, 2019, FEBS letters.

In vitro formation, disposition and toxicity of N-acetoxy-sulfamethoxazole, a potential mediator of sulfamethoxazole toxicity.

D. Grant, M. Miller, S. Spielberg, 1995, The Journal of pharmacology and experimental therapeutics.

Structure-function studies of human arylamine N-acetyltransferases NAT1 and NAT2. Functional analysis of recombinant NAT1/NAT2 chimeras expressed in Escherichia coli.

D. Grant, J. Dupret, G. Goodfellow, 1994, The Journal of biological chemistry.

Identification of amino acids imparting acceptor substrate selectivity to human arylamine acetyltransferases NAT1 and NAT2.

D. Grant, J. Dupret, G. Goodfellow, 2000, The Biochemical journal.

N-acetylation genotype and risk of severe reactions to sulphonamides in AIDS patients.

D. Grant, W. Rozenbaum, C. Deloménie, 1994, British Journal of Clinical Pharmacology.

Genetic polymorphisms of drug metabolism.

D. Grant, U. Meyer, U. Zanger, 1990, Fundamental & clinical pharmacology.

Determination of age and gender differences in biochemical processes affecting the disposition of 2-butoxyethanol and its metabolites in mice and rats to improve PBPK modeling.

D. Grant, K. Weitz, R. Corley, 2005, Toxicology letters.

Loss of PARP7 Increases Type I Interferon Signaling in EO771 Breast Cancer Cells and Prevents Mammary Tumor Growth by Increasing Antitumor Immunity

D. Grant, A. Takaoka, J. Matthews, 2023, Cancers.

Structure-Function Studies of Human Arylamine N-Acetyltransferases NATl and NATB FUNCTIONAL ANALYSIS OF RECOMBINANT NATlMAT2 CHIMERAS EXPRESSED IN ESCHERICHIA COLI*

Geoffrey, D. Grant, Goodfellow, 2001 .

In Vivo and in Vitro Metabolism of Arylamine Procarcinogens in Acetyltransferase-Deficient Mice

D. Grant, K. Sugamori, D. Brenneman, 2006, Drug Metabolism and Disposition.